title: Cost-Effectiveness of Old and New Technologies for Aneuploidy Screening.
abstract: Cost-effectiveness analyses allow assessment of whether marginal gains from new technology are worth increased costs. Several studies have examined cost-effectiveness of Down syndrome (DS) screening and found it to be cost-effective. Noninvasive prenatal screening also appears to be cost-effective among high-risk women with respect to DS screening, but not for the general population. Chromosomal microarray (CMA) is a genetic sequencing method superior to but more expensive than karyotype. In light of CMAs greater ability to detect genetic abnormalities, it is cost-effective when used for prenatal diagnosis of an anomalous fetus. This article covers methodology and salient issues of cost-effectiveness.
authors.affiliation: Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of South Florida, 2 Tampa General Circle, Tampa, FL 33606, USA. Electronic address: rsinkey@health.usf.edu.
authors.forename: Rachel G
authors.initials: RG
authors.lastname: Sinkey
authors.affiliation: Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of South Florida, 2 Tampa General Circle, Tampa, FL 33606, USA.
authors.forename: Anthony O
authors.initials: AO
authors.lastname: Odibo
mesh_terms: D000328:Adult; D003362:Cost-Benefit Analysis; D004314:Down Syndrome / Q000235:genetics*; D005260:Female; D005820:Genetic Testing / Q000191:economics* / Q000379:methods; D017048:Health Care Costs; D006801:Humans; D007621:Karyotyping / Q000191:economics; D020411:Oligonucleotide Array Sequence Analysis / Q000191:economics; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000191:economics* / Q000379:methods
keywords: Cost-benefit analysis; Cost-effectiveness analysis; Down syndrome; Economics; Noninvasive prenatal screening; Prenatal diagnosis–economics